The aggressive nature of breast cancer in young women may be related to the occurrence of mutations in the BRCA1/BRCA2 genes responsible for DNA repair. Despite of cases are associated with and without a family history of breast and ovarian cancer such changes are present in only a small percentage of cases, which corresponds to 80-10% of patients with familial breast cancer and 3.2-10.6% of women with breast cancer non-familial (sporadic). The penetrance rate of this variability is not well understood today, but we know that reproductive factors, risks posed by particular mutations and other genetic modifiers The expression profile of miRNAs can also reveal changes in the regulatory processes that distinguish the appearance of cancer familial and sporadic breast cancer in young patients. miRNAs have been described as related to the aggressiveness of breast cancer and the sensitivity of human mammary tumor strains to antiestrogen. Such evidence indicates that the molecular mechanisms responsible for the aggressive behavior of breast carcinoma in young women has not been sufficiently clarified.
Breast cancer in young women is presented by patients of age or less for 35 years, mostly in the premenopausal women (Walker et al., 1996) . Although this type of cancer is responsible for only 2% of cases of breast cancer, it presents more advanced at diagnosis, histological grade corresponding to a less differentiated (Gajdos et al. 2000; Sidoni et al. 2003; Foxcroft et al., 2004) . The patients also have increased mortality and less disease free survival rate compared to postmenopausal patients (Bertheau et al. 1999; Joslyn, 1999) . Anders et al. (2008) showed that tumoral gene expression profile shown by young women is different from that for postmenopausal women. Such evidence shows that differences in biological behavior of these tumors reflect distinct molecular mechanisms, which can be explained by the fact that the development of each of these tumors occur in different hormonal environments.
Gene expression and breast cancer
The BRCA1 gene was mapped by Hall et al. (1990) Buller, 1999 ; Xu, 1999; Bocher, 2000 , Le Page, 2000 Wang, 2000; Hatman and Ford, 2002) . (Miller, 1996; Scully, 1997a and 1997b; Deng and Brodie, 2000; Wang, 2000; Venkitaraman, 2002; Yarden, 2002; Narod and Foulkes, 2004) .
The BRCA2 gene, whose mutations are responsible for 32% of inherited cases, was mapped by Wooster et al. (1994 and 1995) and featured in the following year by Tavtigian et al. (1996) (Wong, 1997; Smith, 1999; Deng and Brodie, 2000; Kojic, 2003, and Narod Foulkes, 2004; Niwa, 2009 ).
The genes BRCA1 and BRCA2 are (Thorlacius, 1996; Sarantaus, 2000; Vega, 2001) . Classical examples are the mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2, affecting 2 to 2.5% of Ashkenazi Jews, often 10 to 50 times higher than in the general population (Szabo and King, 1997; Ferla, 2007 (Lakhani, 1998; Sobol, 2001; Perou, 2000; Sorlie, 2003) . 
